GPRC5D and AL amyloidosis: Recent results from a Phase I clinical trial (NCT04555551) of CAR‐T cell therapy (MCARH109) targeting GPRC5D confirmed that GPRC5D is an important immunotherapeutic target in multiple myeloma.237